Perspective Therapeutics (NYSE:CATX) Price Target Lowered to $16.00 at Oppenheimer

Perspective Therapeutics (NYSE:CATX) had its price target decreased by Oppenheimer from $22.00 to $16.00 in a report released on Friday morning,Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

Other equities research analysts have also issued research reports about the stock. Truist Financial began coverage on shares of Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price target on the stock. UBS Group started coverage on Perspective Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $20.00 price target on the stock. Bank of America assumed coverage on shares of Perspective Therapeutics in a report on Thursday, July 25th. They issued a “buy” rating and a $24.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $11.00 price target (down from $20.00) on shares of Perspective Therapeutics in a research note on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.14.

Perspective Therapeutics Price Performance

Shares of Perspective Therapeutics stock opened at $3.69 on Friday. The business’s fifty day simple moving average is $11.33. Perspective Therapeutics has a twelve month low of $2.28 and a twelve month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.21). The business had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. As a group, sell-side analysts expect that Perspective Therapeutics will post -0.86 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Perspective Therapeutics by 34.6% in the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after purchasing an additional 4,566,356 shares during the period. Janus Henderson Group PLC acquired a new stake in shares of Perspective Therapeutics during the 1st quarter worth approximately $15,511,000. Virtu Financial LLC bought a new stake in shares of Perspective Therapeutics during the first quarter worth approximately $138,000. Bank of New York Mellon Corp lifted its holdings in Perspective Therapeutics by 214.0% in the second quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company’s stock valued at $1,369,000 after buying an additional 93,548 shares during the period. Finally, Rhumbline Advisers bought a new position in Perspective Therapeutics in the second quarter valued at approximately $630,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.